Gujarat Themis Biosyn incorporates wholly owned Japan unit
Gujarat Themis Biosyn Limited has incorporated a wholly owned subsidiary named Themis Biosyn Japan Limited on May 19, 2026, with a share capital of Ten Lakhs Yen. The subsidiary will operate in the pharmaceutical industry, and the company holds 100% of the shareholding. No specific regulatory approvals were required for the incorporation.
*this image is generated using AI for illustrative purposes only.
Gujarat Themis Biosyn Limited has expanded its global footprint by incorporating a wholly owned subsidiary in Japan. The new entity, named Themis Biosyn Japan Limited, was established on May 19, 2026. This strategic move marks the company's entry into the Japanese market, aligning with its broader business objectives.
Subsidiary Details
The incorporation of Themis Biosyn Japan Limited was completed in compliance with Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The subsidiary is fully owned by Gujarat Themis Biosyn Limited , which holds 100% of its shareholding.
Financial and Operational Information
The newly formed subsidiary has a share capital of Ten Lakhs Yen. As it is a recently incorporated entity, its turnover is currently not applicable. The subsidiary will operate within the pharmaceutical industry, consistent with the parent company's core business sector.
Key Particulars of the Subsidiary
| Sr. No. | Particulars | Details |
|---|---|---|
| (a) | Name of the target entity | Name: Themis Biosyn Japan Limited Country of Incorporation: Japan Share capital: Ten Lakhs Yen |
| (i) | Percentage of shareholding acquired | 100% of the shareholding of Themis Biosyn Japan Limited |
| (j) | Date of Incorporation | May 19, 2026 |
The company has confirmed that no specific governmental or regulatory approvals were required for this incorporation. The business registration extract for the new entity is expected to be received at a later date.
Historical Stock Returns for Gujarat Themis Biosyn
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| +3.25% | -1.15% | +11.45% | -10.66% | +17.72% | +51.44% |
What specific pharmaceutical products or segments is Gujarat Themis Biosyn planning to target in the Japanese market, and how does Japan's stringent regulatory environment compare to their existing markets?
How might the establishment of Themis Biosyn Japan Limited impact the parent company's revenue projections and profitability over the next 3-5 years?
Will Gujarat Themis Biosyn seek local Japanese partnerships or distribution agreements to accelerate market penetration, given Japan's complex pharmaceutical distribution landscape?
19
Access 50+ Readymade Screeners 
Use 200+ Custom Filters 
Get Full Market Insights 
